Who are Visine® for Contacts®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): eye drops (Phenylephrin), placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan, Bolus Phenylephrine/Ephedrine Treatment, Norepinephrine intra-arteriel/hepatic, Oxymetazoline HCL Cream 1.0%, ephedrine and phenylephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/visine-for-contacts.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Visine® for Contacts® — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Visine® for Contacts® (Visine® for Contacts®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic decongestant. Area: Ophthalmology.

marketed Ophthalmic decongestant Alpha-1 adrenergic receptor Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Visine® for Contacts® (Visine® for Contacts®) — Merck Sharp & Dohme LLC. Visine for Contacts is a decongestant eye drop that constricts blood vessels in the eye to reduce redness and irritation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Visine® for Contacts® TARGET	Visine® for Contacts®	Merck Sharp & Dohme LLC	marketed	Ophthalmic decongestant	Alpha-1 adrenergic receptor
eye drops (Phenylephrin)	eye drops (Phenylephrin)	Medical University of Graz	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan	Montefiore Medical Center	marketed	Combination cold and cough remedy	H1 receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); sigma-1 receptor and NMDA receptor (dextromethorphan)
Bolus Phenylephrine/Ephedrine Treatment	Bolus Phenylephrine/Ephedrine Treatment	IWK Health Centre	marketed	Sympathomimetic amines / Vasopressors	Alpha-1 adrenergic receptor (phenylephrine); Alpha and beta adrenergic receptors (ephedrine)
Norepinephrine intra-arteriel/hepatic	Norepinephrine intra-arteriel/hepatic	University Health Network, Toronto	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
Oxymetazoline HCL Cream 1.0%	Oxymetazoline HCL Cream 1.0%	Allergan	marketed	Alpha-1 adrenergic agonist	Alpha-1 adrenergic receptor
ephedrine and phenylephrine	ephedrine and phenylephrine	University Hospital, Clermont-Ferrand	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic decongestant class)

Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Visine® for Contacts® — Competitive Intelligence Brief. https://druglandscape.com/ci/visine-for-contacts. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing